SCA
FLGT icon

Spearhead Capital Advisors’s Fulgent Genetics FLGT Stock Holding History

Spearhead Capital Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,287
Closed -$234K – 121
2022
Q2 		$234K Buy
4,287
+483
+13% +$26.5K 0.03% 152
2022
Q1 		$237K Sell
3,804
-2,072
-35% -$136K 0.03% 170
2021
Q4 		$591K Buy
5,876
+61
+1% +$5.36K 0.07% 86
2021
Q3 		$523K Sell
5,815
-18
-0.3% -$1.64K 0.07% 93
2021
Q2 		$538K Buy
5,833
+622
+12% +$49.7K 0.07% 93
2021
Q1 		$503K Buy
+5,211
New +$538K 0.07% 83

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Spearhead Capital Advisors's FLGT Position: Q3 2022 in Review

Spearhead Capital Advisors sold out of Fulgent Genetics (FLGT) in Q3 2022, closing a stake of 4,287 shares — an estimated $234K sold.

Spearhead Capital Advisors first reported a position in FLGT in Q1 2021 and held it in 6 quarters. The position peaked at $591K in Q4 2021. 235 funds tracked by Wall St. Rank hold FLGT as of Q3 2022.

  • Spearhead Capital Advisors reported no remaining Fulgent Genetics position as of Q3 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 4,287 Fulgent Genetics shares in Q3 2022, an estimated $234K.
  • Spearhead Capital Advisors first reported a position in Fulgent Genetics in Q1 2021 and held it in 6 quarters.
  • Spearhead Capital Advisors's Fulgent Genetics position peaked at $591K in Q4 2021.
  • 235 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2022.

Based on Spearhead Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.